Melanotan-2 vs PT-141 (Bremelanotide) — Peptide Comparison

Melanotan-2 vs PT-141 (Bremelanotide) — Peptide Comparison Melanotan-2 vs PT-141 (Bremelanotide) — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Melanotan-2 100–500 mcg PT-141 (Bremelanotide) 1.75–2 mg Frequency Once daily As needed Administration Subcutaneous injection Cycle Length 4-6 weeks Ongoing/indefinite Onset Speed Moderate (1-2 weeks) Rapid (hours to days) Evidence Level Limited human trials Strong human trials (Phase 3 or FDA approved) Efficacy Tanning Efficacy Sexual Function Tan Longevity Sexual Desire On-Demand Use Clinical Evidence Technical Data Molecular Formula C50H69N15O9 Molecular Weight 1024.18 g/mol Half-Life 33-36 hours Bioavailability High (subcutaneous injection) CAS Number 121062-08-6 C50H68N14O10 1025.2 g/mol 2.7 hours ~100% (subcutaneous injection) 189691-06-3 Protocols starting 0.25 mg (250 mcg) First 3-5 days (loading) Low loading dose used in practice; subcutaneous melanocortin agonism induced melanogenesis at doses as low as 0.25 mg in controlled study [1]. Start low to gauge nausea/flushing. standard 0.5 mg (500 mcg) Continue loading 7-14 days until desired pigmentation Standard loading dose after initial tolerance; subcutaneous administration is the route characterized in clinical pharmacokinetic and tanning studies [1][2]. advanced 2-3 times per week Ongoing maintenance Reduced-frequency maintenance once target pigmentation reached, used in practice to sustain tanning [3]. 1 mg As needed, ~45 min before sexual activity; no more than once per 24 h Trial period (assess response/tolerability) Lower 1 mg trial dose used in practice to gauge nausea tolerance before moving to the FDA dose [6]. Inject into abdomen or thigh. 1.75 mg As needed, ~45 min before sexual activity; max once per 24 h and 8 doses per 28 days Ongoing as needed FDA-approved Vyleesi dose for hypoactive sexual desire disorder in premenopausal women; efficacy shown in the RECONNECT phase 3 trials [1][6]. Applications Fair-Skinned Individuals Who Struggle to Tan If you're the type who burns before you bronze, MT-2 can be a game-changer. It works by telling your skin cells to produce more melanin—the pigment that creates a tan. People who normally can't tan often see the most dramatic results. Those Wanting to Reduce Sun Exposure MT-2 means you need far less UV exposure to develop and maintain a tan. A few minutes of sun or a brief tanning bed session goes much further. This could potentially reduce your cumulative UV damage over time. Year-Round Tan Maintenance Unlike a natural tan that fades quickly, MT-2 tans last longer and can be maintained year-round with minimal upkeep. Many users find they can keep their summer color through winter with just weekly maintenance doses. Those Experiencing Low Libido MT-2 has significant effects on sexual arousal and function in both men and women. While PT-141 is more targeted for this purpose, some users appreciate getting tanning and libido benefits from one peptide. Women with Low Sexual Desire (HSDD) PT-141 is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder—when you used to have normal desire but it's faded, and it's causing real distress in your life. It's the only approved treatment that works through brain pathways rather than hormones. Men Who Don't Respond to Viagra-Type Medications While not FDA-approved for men, clinical research shows PT-141 may help men with erectile dysfunction who don't respond to PDE5 inhibitors like Viagra or Cialis. Because it works through the brain rather than blood vessels, it offers a completely different approach. Those Wanting On-Demand Treatment Unlike daily medications like flibanserin (Addyi), PT-141 is used only when you want it—take it 45 minutes before intimacy. This gives you control over timing without committing to daily pills. People Seeking to Address the 'Wanting' Part of Intimacy Many sexual health treatments focus on the physical mechanics (blood flow, lubrication). PT-141 is unique because it targets desire itself—the psychological 'wanting' that initiates intimacy. It works on your brain's arousal circuits. Safety Profile Common Facial flushing Nausea Darkening of moles and freckles Spontaneous erections (men) Drowsiness and fatigue Uncommon New mole formation Headaches Serious Priapism (prolonged erection) Concerning mole changes Headache Injection site reactions Skin darkening (hyperpigmentation) Blood pressure increase Research Status FDA Status Not FDA approved Safety Overview Melanotan-2 has been studied in clinical trials and shows a generally acceptable short-term safety profile when used as directed. The most common side effects—nausea and flushing—are usually temporary and decrease with continued use. However, MT-2 is not FDA approved, and long-term safety data is limited. The main safety concern is the unknown effect on melanocytes (pigment-producing cells), particularly in people with a history of melanoma or atypical moles. Contraindications xHistory of melanoma or skin cancer xFamily history of melanoma xLarge number of atypical moles xPregnancy or breastfeeding xSevere cardiovascular disease FDA approved for this use PT-141 has undergone rigorous FDA review and was approved in 2019 based on two large Phase 3 clinical trials involving over 1,200 women. The most common side effect is nausea (affecting about 40% of users), which typically decreases with repeated use. The drug causes transient increases in blood pressure (average 2-3 mmHg) and slight decreases in heart rate, which is why it's contraindicated in uncontrolled hypertension. Long-term safety data from the 52-week extension study showed no new safety concerns. xUncontrolled high blood pressure xCardiovascular disease xHistory of heart attack or stroke xPregnancy or planning pregnancy xCurrently breastfeeding Decision Guide Choose Melanotan-2 if... Achieving a natural-looking tan Reducing sun exposure time Enhancing libido and sexual function Appetite suppression Choose PT-141 (Bremelanotide) if... Restoring sexual desire Treating hypoactive sexual desire disorder (HSDD) Enhancing arousal response Supporting intimacy when desire is low